Soaanz is owned by Sarfe Pharms.
Soaanz contains Torsemide.
Soaanz has a total of 1 drug patent out of which 0 drug patents have expired.
Soaanz was authorised for market use on 14 June, 2021.
Soaanz is available in tablet;oral dosage forms.
The generics of Soaanz are possible to be released after 06 October, 2033.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10154963 | SARFE PHARMS | Controlled-release formulations comprising Torsemide |
Oct, 2033
(10 years from now) |
Drugs and Companies using TORSEMIDE ingredient
Market Authorisation Date: 14 June, 2021
Treatment: NA
Dosage: TABLET;ORAL
8
United States
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic